Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

BACKGROUND: Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid unnecessary harms from treatment. The new 21-gene assay (OncotypeDX,...

詳細記述

保存先:
書誌詳細
出版年:BMC Cancer
主要な著者: Jahn, Beate, Rochau, Ursula, Kurzthaler, Christina, Hubalek, Michael, Miksad, Rebecca, Sroczynski, Gaby, Paulden, Mike, Bundo, Marvin, Stenehjem, David, Brixner, Diana, Krahn, Murray, Siebert, Uwe
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2017
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5644100/
https://ncbi.nlm.nih.gov/pubmed/29037213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3603-z
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料